0.00Open0.00Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV1.01%PremiumMay 17, 2024Expiry Date1.48Intrinsic Value100Multiplier-1DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma1.32Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Xeris Pharmaceuticals Stock Discussion
Xeris Biopharma: Potential to Get Development Payments, Plus Low Double-Digit Royalties Based on Future Sales of Xeris Glucagon for Pumps, Pump Systems
Xeris Biopharma Enters Into An Exclusive Worldwide License Agreement With Amgen For Xeriject Formulation Of Teprotumumab For Thyroid Eye Disease; Xeris Has The Potential To Receive $75M In Development And Regulatory Milestones
No comment yet